vs
Side-by-side financial comparison of Pineapple Financial Inc. (PAPL) and PLUS THERAPEUTICS, INC. (PSTV). Click either name above to swap in a different company.
PLUS THERAPEUTICS, INC. is the larger business by last-quarter revenue ($1.4M vs $707.3K, roughly 1.9× Pineapple Financial Inc.). PLUS THERAPEUTICS, INC. runs the higher net margin — -417.9% vs -2756.2%, a 2338.3% gap on every dollar of revenue. On growth, PLUS THERAPEUTICS, INC. posted the faster year-over-year revenue change (-3.2% vs -4.8%). Pineapple Financial Inc. produced more free cash flow last quarter ($-3.3M vs $-6.3M). Over the past eight quarters, Pineapple Financial Inc.'s revenue compounded faster (-2.0% CAGR vs -9.7%).
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company headquartered in Houston, Texas, that develops targeted radiotherapeutics and diagnostic services for brain and central nervous system (CNS) cancers. The company’s lead therapeutic candidate, marketed as REYOBIQ™, is an investigational liposomal radiopharmaceutical under clinical evaluation for recurrent glioblastoma, leptomeningeal metastases, and certain pediatric brain cancers. Plus Therapeutics also commercialized a molecu...
PAPL vs PSTV — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $707.3K | $1.4M |
| Net Profit | $-19.5M | $-5.7M |
| Gross Margin | 48.9% | — |
| Operating Margin | -2518.8% | -420.0% |
| Net Margin | -2756.2% | -417.9% |
| Revenue YoY | -4.8% | -3.2% |
| Net Profit YoY | -3174.1% | -46.4% |
| EPS (diluted) | $-1.21 | $0.95 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $707.3K | — | ||
| Q4 25 | $721.7K | $1.4M | ||
| Q3 25 | $730.5K | $1.4M | ||
| Q2 25 | $746.9K | $1.4M | ||
| Q1 25 | $743.3K | $1.1M | ||
| Q4 24 | $766.1K | $1.4M | ||
| Q3 24 | $598.3K | $1.5M | ||
| Q2 24 | $736.4K | $1.3M |
| Q1 26 | $-19.5M | — | ||
| Q4 25 | $-6.4M | $-5.7M | ||
| Q3 25 | $-1.8M | $-4.4M | ||
| Q2 25 | $-557.7K | $5.2M | ||
| Q1 25 | $-595.4K | $-17.4M | ||
| Q4 24 | $-656.9K | $-3.9M | ||
| Q3 24 | $-1.7M | $-2.9M | ||
| Q2 24 | $-848.6K | $-2.9M |
| Q1 26 | 48.9% | — | ||
| Q4 25 | 49.6% | — | ||
| Q3 25 | 27.8% | — | ||
| Q2 25 | 67.6% | — | ||
| Q1 25 | 43.4% | — | ||
| Q4 24 | 45.9% | — | ||
| Q3 24 | 43.2% | — | ||
| Q2 24 | 44.2% | — |
| Q1 26 | -2518.8% | — | ||
| Q4 25 | -909.1% | -420.0% | ||
| Q3 25 | -131.3% | -320.8% | ||
| Q2 25 | -93.3% | -110.6% | ||
| Q1 25 | -80.6% | -333.9% | ||
| Q4 24 | -90.5% | -276.2% | ||
| Q3 24 | -232.8% | -260.9% | ||
| Q2 24 | -121.7% | -289.1% |
| Q1 26 | -2756.2% | — | ||
| Q4 25 | -891.6% | -417.9% | ||
| Q3 25 | -250.3% | -316.6% | ||
| Q2 25 | -74.7% | 370.6% | ||
| Q1 25 | -80.1% | -1643.2% | ||
| Q4 24 | -85.7% | -276.4% | ||
| Q3 24 | -283.9% | -197.4% | ||
| Q2 24 | -115.2% | -229.9% |
| Q1 26 | $-1.21 | — | ||
| Q4 25 | $-4.79 | $0.95 | ||
| Q3 25 | $-0.93 | $-0.04 | ||
| Q2 25 | $-0.05 | $-0.01 | ||
| Q1 25 | $-1.73 | $-1.19 | ||
| Q4 24 | $-2.60 | $-0.51 | ||
| Q3 24 | $-11.10 | $-0.37 | ||
| Q2 24 | $-0.12 | $-0.71 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $8.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $27.1M | $4.0M |
| Total Assets | $48.9M | $16.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $8.6M | ||
| Q3 25 | — | $16.6M | ||
| Q2 25 | — | $6.9M | ||
| Q1 25 | — | $9.9M | ||
| Q4 24 | — | $3.6M | ||
| Q3 24 | — | $4.8M | ||
| Q2 24 | — | $8.4M |
| Q1 26 | $27.1M | — | ||
| Q4 25 | $-5.5M | $4.0M | ||
| Q3 25 | $906.7K | $5.1M | ||
| Q2 25 | $842.6K | $3.0M | ||
| Q1 25 | $739.7K | $-23.6M | ||
| Q4 24 | $1.3M | $-8.9M | ||
| Q3 24 | $1.3M | $-5.2M | ||
| Q2 24 | $2.0M | $-7.6M |
| Q1 26 | $48.9M | — | ||
| Q4 25 | $10.6M | $16.3M | ||
| Q3 25 | $5.4M | $18.7M | ||
| Q2 25 | $4.7M | $10.3M | ||
| Q1 25 | $4.0M | $12.1M | ||
| Q4 24 | $4.1M | $6.6M | ||
| Q3 24 | $4.1M | $7.0M | ||
| Q2 24 | $4.3M | $11.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-3.3M | $-6.3M |
| Free Cash FlowOCF − Capex | $-3.3M | $-6.3M |
| FCF MarginFCF / Revenue | -462.7% | -459.9% |
| Capex IntensityCapex / Revenue | 0.0% | 2.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-20.8M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $-3.3M | — | ||
| Q4 25 | $-489.7K | $-6.3M | ||
| Q3 25 | $-507.6K | $-2.5M | ||
| Q2 25 | $397.0K | $-5.8M | ||
| Q1 25 | $-172.6K | $-6.2M | ||
| Q4 24 | $-663.6K | $-1.2M | ||
| Q3 24 | $-264.7K | $-3.7M | ||
| Q2 24 | $123.0K | $-1.1M |
| Q1 26 | $-3.3M | — | ||
| Q4 25 | $-491.7K | $-6.3M | ||
| Q3 25 | — | $-2.6M | ||
| Q2 25 | — | $-5.8M | ||
| Q1 25 | — | $-6.2M | ||
| Q4 24 | — | $-1.2M | ||
| Q3 24 | $-264.7K | $-3.7M | ||
| Q2 24 | $122.7K | $-1.2M |
| Q1 26 | -462.7% | — | ||
| Q4 25 | -68.1% | -459.9% | ||
| Q3 25 | — | -184.3% | ||
| Q2 25 | — | -417.6% | ||
| Q1 25 | — | -583.1% | ||
| Q4 24 | — | -86.5% | ||
| Q3 24 | -44.2% | -253.7% | ||
| Q2 24 | 16.7% | -96.2% |
| Q1 26 | 0.0% | — | ||
| Q4 25 | 0.3% | 2.2% | ||
| Q3 25 | — | 1.9% | ||
| Q2 25 | — | 0.5% | ||
| Q1 25 | — | 0.3% | ||
| Q4 24 | — | 0.8% | ||
| Q3 24 | 0.0% | 1.0% | ||
| Q2 24 | 0.0% | 6.3% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -1.13× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
